J&J Increases European Consumer Stake With Merck Buyout
This article was originally published in The Tan Sheet
Executive Summary
Merck says it will seek new partners for future Rx-to-OTC switch drugs in Europe following Johnson & Johnson's buyout of the company's half of their European consumer health joint venture
You may also be interested in...
Tylenol Gains On COX-2 Fallout, Drives J&J Consumer Sales
Tylenol first-quarter sales benefited from the publicity surrounding COX-2 safety issues, according to Johnson & Johnson
Zocor UK Switch Decision Could Be Moved Up
The British Department of Health could decide to switch Merck's Zocor (simvastatin) to behind-the-counter status in the UK by late March
Rx Firms Keeping A Close Eye On Lagging OTC Market Growth
Roche's decision to shop its OTC unit is an example of a pharmaceutical company putting increased profit margins ahead of long-term steady cash flow